Trial Profile
A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Arazasetron (Primary) ; Cisplatin
- Indications Chemotherapy-induced damage; Hearing loss
- Focus Proof of concept; Therapeutic Use
- Acronyms NOTOXIS
- Sponsors Sensorion
- 14 Mar 2024 According to a Sensorion media release, company will communicate preliminary efficacy and safety data of this POC Phase 2a clinical study of SENS-401 in CIO during the World Congress of Audiology, held on September 19-22, 2024, in Paris, France.
- 09 Feb 2024 According to a Sensorion media release, the company will present preliminary safety and efficacy data at World Congress of Audiology in H2 2024.
- 18 Dec 2023 According to a Sensorion media release, recruitment is progressing at a sustained path, with 11 clinical centers open to date. Management team will communicate further updates during the World Congress of Audiology 2024.